Please check your internet connection and try again.
# Ezivac Enema
## Overview
Ezivac enema is a hypertonic osmotic laxative containing sodium phosphates (monobasic sodium phosphate and dibasic sodium phosphate). It works by drawing water into the lumen of the colon, inducing peristalsis and evacuation.
## Primary Indications
Treatment of occasional constipation and bowel cleansing prior to rectal examinations or surgery.
## Adult Dosing
* **Constipation:** 1 unit (118 mL) administered rectally as a single dose.
* **Bowel preparation:** Follow specific institutional protocol. Typically 1 to 2 units administered as directed by clinical procedure.
## Pediatric Dosing
* **Children 12 years and older:** Same as adult dosing.
* **Children 2–11 years:** 0.5 unit (approx. 59 mL) or as directed by a healthcare professional. Use pediatric-sized tip/volume products if available.
* **Children under 2 years:** Contraindicated.
## Dose Adjustments
* **Renal Impairment:** Use with extreme caution. High risk of hyperphosphatemia, hypocalcemia, hypernatremia, and acidosis. Avoid in patients with significant chronic kidney disease.
* **Geriatric:** Use with caution due to the higher risk of electrolyte imbalances and dehydration.
## Contraindications
* Hypersensitivity to any component.
* Congestive heart failure.
* Ascites.
* Known or suspected bowel obstruction, perforation, or toxic megacolon.
* Acute surgical abdomen or inflammatory bowel disease (active).
* Renal failure or severe electrolyte disturbance.
## Adverse Effects
* **Common:** Abdominal cramping, nausea, anal irritation, and localized discomfort.
* **Serious:** Severe electrolyte disturbances (hyperphosphatemia, hypocalcemia, hypokalemia, hypernatremia), dehydration, metabolic acidosis, and rectal mucosal injury/ulceration with improper use.
## Key Drug Interactions
* **Diuretics (Loop/Thiazide):** Increased risk of dehydration and electrolyte imbalances.
* **ACE Inhibitors/ARBs:** Increased risk of renal impairment and electrolyte toxicity.
* **Calcium Channel Blockers:** Use caution; potential for additive effects on electrolyte levels.
* **NSAIDs:** Avoid concurrent use if there is renal impairment; increased risk of nephrotoxicity.
## Monitoring
* Serum electrolytes (Sodium, Potassium, Calcium, Phosphate, Creatinine, and BUN) in at-risk patients (elderly, renal impairment).
* Hydration status.
* Frequency and characteristics of bowel movements.
## Clinical Pearls
* **Administration:** Lubricate the rectal tip before insertion. Instruct the patient to lie on the left side with knees bent (Sims' position). Do not force the tip into the rectum.
* **Hydration:** Advise patients to maintain adequate oral fluid intake to prevent dehydration.
* **Duration:** Should not be used for more than 7 consecutive days. Chronic use can lead to laxative dependence.
* **Note:** If no bowel movement occurs after administration, contact a physician immediately to rule out obstruction.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical protocols vary by institution. Always verify specific dosing, safety information, and contraindications against the current manufacturer’s prescribing information and your facility’s clinical guidelines before administration.
